HYBRID EVENT: You can participate in person at London, UK or Virtually from your home or work.
ICC 2019

Mona Magdy Saber Moawad

Mona Magdy Saber Moawad, Speaker at  Cancer Conferences
Cairo University, Egypt
Title : Utilizing nano-cubosomes in cancer treatment


Despite the variant incidence of CRC, among different countries it remains the third most common type of cancer and leading cause of cancer deaths worldwide. Cisplatin, the most common chemotherapy drug used in solid tumor treatment, is used in combination with other drugs to produce synergistic effects in eradicating cancer cells, while keeping its side effects to a minimal. Nano-cubosomes, thanks to the advantages of their liquid crystalline porous nano-architecture and capability for multi-drug encapsulation, appear to be of interest as nanocarriers for anticancer therapies. Hence, delivering cisplatin, as nano-cubosomes, concomitantly with other chemo-dugs can lead to a rationally designed therapy for chemo-resistant cancers and might overcome problems associated with conventional cisplatin treatment. The aim of the present study was to construct nano-cubosomes bearing cisplatin, metformin and cisplatin-metformin combination and investigate their effect on proliferation in Caco-2 and HCT-116 cell lines, as well as, tumorigenesis-associated metabolic markers in HCT-116 CRC cell lines. Results from this study revealed that nanocubosomal formulations exhibited superior cytotoxic effect compared to unformulated cisplatin. This cytotoxic effect was profound upon incorporation of metformin, an mTOR inhibitor, in cisplatin nano-cubosomes. The induced CRC cell apoptosis was through inhibition of several metabolic pathways, namely, AMPK/mTOR and Akt/mTOR. Drugloaded nano-cubosomes ensued depletion in glucose and energy levels that led to AMPK activation and thus mTOR inhibition. mTOR was additionally inhibited via suppression of p-Akt levels after nano-cubosomal treatment. Moreover, drug-loaded nano-cubosomes produced a notable escalation in ROS levels, evident as an increase in NADPH oxidase, inhibition of LDH and a consequential upsurge in caspase-3. These results demonstrated the influence exerted by low concentrations of cisplatin-loaded nano-cubosomes on CRC cell survival and enhancement of their cytotoxicity upon metformin addition.


I completed my PhD from Cairo University in 2018. I am currently a lecturer in the Pharmacology and Toxicology department, a premier research organization. I published 2 articles related to colorectal cancer in the BMC Cancer journal. I spent 6 months in the institute of molecular medicine in Heinrich Heine University, Düsseldorf, Germany. This was a German Egyptian Research Short term scholarship funded by the DAAD (Deutscher Akademischer Austauchdienst). I have attended several international and national conferences including but not limited to; European cancer congress (ESMO 2015), 12th and 13th congress of EACPT, 2016 and 2017 conference of BGICC.